| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1537-2995.1992.32692367207.X |
| P698 | PubMed publication ID | 1502715 |
| P2093 | author name string | S. B. Moore | |
| M. A. Popovsky | |||
| Chaplin HC Jr | |||
| H. C. Chaplin | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | health policy | Q1519812 |
| acute lung injury | Q4677935 | ||
| P304 | page(s) | 589-592 | |
| P577 | publication date | 1992-07-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy | |
| P478 | volume | 32 |
| Q43556866 | A randomized controlled trial oftransfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? |
| Q46762351 | Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital |
| Q33362738 | Acute lung injury after blood transfusion in mechanically ventilated patients |
| Q41923262 | Anti-granulocyte antibody screening with extracted granulocyte antigens by a micro-mixed passive hemagglutination method |
| Q34203372 | Assessment of Intraoperative Blood Loss during Oral and Maxillofacial Surgical Procedures in a Nigerian Tertiary Health Care Center |
| Q40705119 | Autohaemotherapy after treatment of blood with ozone. A reappraisal |
| Q33624849 | Autologous transfusion and reducing allogeneic blood exposure |
| Q84020823 | Bad blood: a trigger for TRALI |
| Q37715077 | Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality |
| Q36833050 | Characterizing the epidemiology of postoperative transfusion-related acute lung injury |
| Q37871065 | Clinical relevance of the HLA system in blood transfusion |
| Q52010790 | Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. |
| Q41139355 | Cumulative effect in transfusion related acute lung injury. |
| Q74241511 | Detection by flow cytometry of antibodies against surface and intracellular granulocyte antigens |
| Q28765218 | Diatom succession trends in recent sediments from Lake Baikal and their relation to atmospheric pollution and to climate change |
| Q35991946 | Economics of pathogen inactivation technology for platelet concentrates in Japan |
| Q35194576 | Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment--final report |
| Q38260255 | Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation |
| Q37102020 | Erythropoietic agents for anemia of critical illness |
| Q51990513 | Flow-cytometric approach to the prompt laboratory diagnosis of TRALI: a case report. |
| Q56675460 | Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant |
| Q47741465 | HLA class II antibodies in transfusion-related acute lung injury (TRALI). A case report |
| Q45957230 | HLA class II antibodies in transfusion-related acute lung injury. |
| Q35925724 | Hypotension and acute pulmonary insufficiency following transfusion of autologous red blood cells during surgery: a case report and review of the literature |
| Q26752496 | Impact of Transfusion on Cancer Growth and Outcome |
| Q40579240 | Investigating transfusion-related acute lung injury (TRALI). |
| Q33504985 | Labile blood products from donors immunized against the HLA system. Apropos of a case of transfusional pulmonary edema |
| Q34022474 | Leucocyte depletion of the blood supply - how will patients benefit? |
| Q33776826 | Long-term survival and quality of life after transfusion-associated pulmonary edema in critically ill medical patients |
| Q40295147 | Lung microvascular endothelial cell injury caused by treatment with polymorphonuclear neutrophils and low-IgM serum: a model of transfusion-related acute lung injury |
| Q33361167 | Optimizing platelet transfusion therapy |
| Q36821356 | Perioperative blood transfusion: a plea for guidelines |
| Q33564923 | Possible transfusion-related acute lung injury (TRALI) in cardiac surgery patients |
| Q35737035 | Pulmonary injury from transfusion-related acute lung injury |
| Q40204726 | Recurrent transfusion-related acute lung injury after a two-year interval |
| Q40607264 | Red Cell Transfusion Triggers and Postoperative Outcomes After Major Surgery. |
| Q36392495 | Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study |
| Q35824949 | Regional transfusion centre preoperative autologous blood donation programme: the first two years |
| Q41699359 | Reporting serious hazards of transfusion: the SHOT program |
| Q50473056 | Residual plasma in red blood cells and transfusion-related acute lung injury. |
| Q37133672 | Retrospective evaluation of adverse transfusion reactions following blood product transfusion from a tertiary care hospital: A preliminary step towards hemovigilance |
| Q51676960 | TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. |
| Q44294156 | TRALI in the University Hospital of Nancy: a reevaluation of the incidence after applying strict criteria of Toronto |
| Q37854505 | The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists |
| Q37915434 | Therapeutic apheresis in critically ill patients |
| Q38012503 | Therapeutic options for transfusion related acute lung injury; the potential of the G2A receptor |
| Q34333864 | Transfusion and lung injury |
| Q35812945 | Transfusion and the lung: circulatory overload and acute lung injury |
| Q34205820 | Transfusion reactions |
| Q34791015 | Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention |
| Q79192198 | Transfusion-related acute lung injury |
| Q87329613 | Transfusion-related acute lung injury |
| Q28255426 | Transfusion-related acute lung injury |
| Q73702306 | Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma |
| Q36562864 | Transfusion-related acute lung injury (TRALI): current clinical and pathophysiologic considerations |
| Q35100910 | Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. |
| Q33344069 | Transfusion-related acute lung injury during plasma exchange: Suspecting the unsuspected |
| Q47788677 | Transfusion-related acute lung injury following PDA ligation in a preterm neonate. |
| Q42208037 | Transfusion-related acute lung injury in multiple traumatized patients. |
| Q36054831 | Transfusion-related acute lung injury in the Canadian paediatric population |
| Q71589737 | Transfusion-related acute lung injury treated with surfactant in a neonate |
| Q33610835 | Transfusion-related acute lung injury. |
| Q51694757 | Transfusion-related acute lung injury: a 5-year look-back study. |
| Q36546623 | Transfusion-related acute lung injury: a literature review |
| Q38115585 | Transfusion-related acute lung injury: advances in understanding the role of proinflammatory mediators in its genesis |
| Q77421271 | [A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)] |
Search more.